← Leaderboards
Angeles Alvarez Secord
Duke University
$1,416,047
Attributed
$5,883,177
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $723.6K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,883,177 · 4
By mechanism
UG1$3,094,644 · 1
U10$2,019,512 · 1
R21$769,021 · 2
Top collaborators
- Daniel P Barboriak12 shared
- Jeffrey None Crawford12 shared
- Eun-Sil Shelley Hwang12 shared
- David M Brizel7 shared
- Linda Sutton7 shared
- Harry Paul Erba6 shared
- Manisha Palta3 shared
- Christopher Kelsey2 shared
Most similar at Duke University
Same institution · by research overlap
- Jeffrey None Crawford$10,066,024
- Herbert I Hurwitz$4,193,162
- Michael Barry Kastan$65,974,699
- Thomas L Ortel$32,805,539
- David M Brizel$856,724
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureMalignant NeoplasmsResourcesEnrollmentCancer TherapyClinical TrialsBaseTherapy DevelopmentMemberAmerican College Of Radiology Imaging NetworkLeadershipFacultyConduct Clinical TrialsMentorsEastern Cooperative Oncology GroupImageInterdisciplinary StudyFundingClinical ResearchBiologyAdultCommunitiesFosteringGrant
Grant awards (16)
NCI National Clinical Trials Network (UG1)$406,019
UG1 · FY2025 · CA
NCI National Clinical Trials Network (UG1)$410,792
UG1 · FY2024 · CA
NCI National Clinical Trials Network (UG1)$439,350
UG1 · FY2023 · CA
NCI National Clinical Trials Network (UG1)$447,677
UG1 · FY2022 · CA
Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240$123,270
R21 · FY2022 · CA · contact PI
NCI National Clinical Trials Network (UG1)$455,656
UG1 · FY2021 · CA
Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240$267,952
R21 · FY2021 · CA · contact PI
NCI National Clinical Trials Network (UG1)$463,561
UG1 · FY2020 · CA
NCI National Clinical Trials Network (UG1)$471,589
UG1 · FY2019 · CA
NCI National Clinical Trials Network U10$413,627
U10 · FY2018 · CA
NCI National Clinical Trials Network U10$392,946
U10 · FY2017 · CA
NCI National Clinical Trials Network U10$392,946
U10 · FY2016 · CA
NCI National Clinical Trials Network U10$411,893
U10 · FY2015 · CA
Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer$207,061
R21 · FY2015 · CA · contact PI
NCI National Clinical Trials Network U10$408,100
U10 · FY2014 · CA
Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer$170,738
R21 · FY2014 · CA · contact PI